OncoMatch/Clinical Trials/NCT06966024

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Is NCT06966024 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies DCC-2812 for renal cell carcinoma.

Phase 1RecruitingDeciphera Pharmaceuticals, LLCNCT06966024Data as of May 2026

Treatment: DCC-2812 — This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Renal Cell Carcinoma

Urothelial Carcinoma

Prostate Cancer

Disease stage

Metastatic disease required

Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer

Prior therapy

Cannot have received: anticancer therapy

Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812

Lab requirements

Blood counts

Kidney function

Liver function

Adequate organ function and electrolytes

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Dana-Farber Cancer Institute · Boston, Massachusetts
NEXT Oncology, Austin · Austin, Texas
NEXT Oncology, San Antonio · San Antonio, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify